Archive for the ‘biotechnology’ Category
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress
ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals [...]
In: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, biotechnology · Tagged with: Biotech, Biotech CEO of the Year, biotechnology, Chief executive officer, Fuad El-Hibri
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Share, Trubion Pharmaceuticals, biotechnology · Tagged with: BioSolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals
Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, biotechnology · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States, US government
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (EBS 15.96, -0.03, -0.19%) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland’s outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, [...]
In: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, U.S. Food and Drug Administration, biotechnology · Tagged with: Baltimore, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Maryland
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
In: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, Strategic National Stockpile, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Board of directors, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Leadership, Shareholders, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Biotechnology and Pharmaceuticals, Chief executive officer, Emergent BioSolutions, U.S. Food and Drug Administration